668 related articles for article (PubMed ID: 10082174)
1. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
Wangemann M; Retzow A; Vens-Cappell B
Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
[TBL] [Abstract][Full Text] [Related]
2. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
[TBL] [Abstract][Full Text] [Related]
3. Influence of food on the pharmacokinetics of a new multiple unit sustained release sodium valproate formulation.
Retzow A; Vens-Cappell B; Wangemann M
Arzneimittelforschung; 1997 Dec; 47(12):1347-50. PubMed ID: 9450162
[TBL] [Abstract][Full Text] [Related]
4. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
Dulac O; Alvarez JC
Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
[TBL] [Abstract][Full Text] [Related]
5. Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers.
Roberts D; Easter D; O'Bryan-Tear G
Biopharm Drug Dispos; 1996 Mar; 17(2):175-82. PubMed ID: 8907724
[TBL] [Abstract][Full Text] [Related]
6. Different serum concentrations of steady-state valproic acid in two sustained-release formulations.
Yasui-Furukori N; Saito M; Nakagami T; Niioka T; Sato Y; Fujii A; Kaneko S
Psychiatry Clin Neurosci; 2007 Jun; 61(3):308-12. PubMed ID: 17472600
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects.
Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S
Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728
[TBL] [Abstract][Full Text] [Related]
8. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
9. [The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].
Yang XG; Nie SF; Bai HJ; Zhang GJ; Pan WS
Yao Xue Xue Bao; 2005 May; 40(5):457-61. PubMed ID: 16220793
[TBL] [Abstract][Full Text] [Related]
10. Study on the dose proportionality of the pharmacokinetics of sustained release sodium valproate.
Wangemann M; Retzow A; Mazur D; Vens-Cappell B
Int J Clin Pharmacol Ther; 2000 Aug; 38(8):395-401. PubMed ID: 10984013
[TBL] [Abstract][Full Text] [Related]
11. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
Dutta S; Reed RC
Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the bioavailability of 250 and 500 mg divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Zhang Y; Lee LL; O'Dea R
Biopharm Drug Dispos; 2004 Nov; 25(8):353-7. PubMed ID: 15378556
[TBL] [Abstract][Full Text] [Related]
13. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Reed RC; Cavanaugh JH
J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
[TBL] [Abstract][Full Text] [Related]
14. Bioavailability of divalproex extended-release formulation relative to the divalproex delayed-release formulation.
Dutta S; Zhang Y
Biopharm Drug Dispos; 2004 Nov; 25(8):345-52. PubMed ID: 15378557
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability study of two carbamazepine containing sustained release formulations after multiple oral dose administration.
Wangemann M; Retzow A; Evers G; Mazur D; Schug B; Blume H
Arzneimittelforschung; 1998 Dec; 48(12):1131-7. PubMed ID: 9893926
[TBL] [Abstract][Full Text] [Related]
16. [Biological availability of gastric juice-resistant coated diclofenac preparations. 1. Bioavailability study following a single administration of a multiple-unit formulation in comparison with a single-unit formulation].
Scheidel B; Blume H; Walter K; von Nieciecki A; Babej-Dölle RM
Arzneimittelforschung; 1993 Nov; 43(11):1211-5. PubMed ID: 8292067
[TBL] [Abstract][Full Text] [Related]
17. Bioavailability of theophylline from a sustained-release aminophylline formulation (Euphyllin retard tablets)--plasma levels after single and multiple oral doses.
Schuppan D; Molz KH; Staib AH; Rietbrock N
Int J Clin Pharmacol Ther Toxicol; 1981 May; 19(5):223-7. PubMed ID: 7251238
[TBL] [Abstract][Full Text] [Related]
18. Relative bioavailability of different valproic acid formulations.
Franke G; Diletti E; Hoffmann C; Zschiesche M; Scheuch E; Siegmund W
Int J Clin Pharmacol Ther; 1995 Dec; 33(12):653-7. PubMed ID: 8963482
[TBL] [Abstract][Full Text] [Related]
19. Suprofen sustained release kinetics in healthy male volunteers. 1st communication: a single dose open crossover bioavailability study of suprofen sustained release tablets versus capsules.
Michos N; Zulliger HW; Barkworth MF; Johnson KJ; Rehm KD; Töberich H; Klein G
Arzneimittelforschung; 1986 Jun; 36(6):941-8. PubMed ID: 3741528
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic profile of a new sustained-release theophylline pellet formulation for once-daily evening administration.
Steinijans VW; Sauter R; Böhm A; Staudinger H
Arzneimittelforschung; 1988 Aug; 38(8A):1241-50. PubMed ID: 3190813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
